Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

 
• By Mandy Jackson

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Microscopic image of a gastrointestinal stromal tumor (GIST). Malignant potential depends on size, location and mitotic activity. Targeted therapy with Imatinib (Gleevec) may prevent recurrence. - Image
Deciphera's ripretinib targets GIST cells with KIT and PDGFRa mutations. • Source: Shutterstock

More from Clinical Trials

More from R&D